The current challenges for vaccine development

Journal of Medical Microbiology

Volumn 61, Issue PART7, 2012, Pages 889-894

  Oyston, Petra ^a   Robinson, Karen ^b  

^a Biomedical Sciences   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN BINDING; COST BENEFIT ANALYSIS; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; LICENSING; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROFIT; REVIEW; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; VACCINES;

EID: 84862665338     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.039180-0     Document Type: Review

References (55)

1. Baz Morelli, A., Becher, D., Koernig, S., Silva, A., Drane, D. & Maraskovsky, E. (2012). ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 61, 935-943.
2. Beernink, P. T., Shaughnessy, J., Braga, E. M., Liu, Q., Rice, P. A., Ram, S. & Granoff, D. M. (2011). A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186, 3606-3614.
3. Butler, D. (2011). Vaccine campaign to target deadly childhood diarrhoea. Nature 477, 519.
4. Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A. & other authors (2011). A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856.
5. Dannenberg, A. M., Jr (2010). Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev 23, 781-794.
6. Duewell, P., Kisser, U., Heckelsmiller, K., Hoves, S., Stoitzner, P., Koernig, S., Morelli, A. B., Clausen, B. E., Dauer, M. & other authors (2011). ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective crosspriming of CD8+ T cells. J Immunol 187, 55-63.
7. Ebensen, T. & Guzmán, C. A. (2009). Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Adv Exp Med Biol 655, 171-188.
8. Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M., Goudsmit, J. & Wilson, I. A. (2009). Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251.
9. Ekiert, D. C., Friesen, R. H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H. J. & other authors (2011). A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850.
10. Elias, D., Wolday, D., Akuffo, H., Petros, B., Bronner, U. & Britton, S. (2001). Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination. Clin Exp Immunol 123, 219-225.
11. Enserink, M. (2010). Global public health. What's next for disease eradication? Science 330, 1736-1739.
12. Ferreira, D. M., Jambo, K. C. & Gordon, S. B. (2011). Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol 19, 464-470.
13. GAVI Alliance (2011). http://www.gavialliance.org/ Date accessed 5 October 2011.
14. Gibbons, D. L. & Spencer, J. (2011). Mouse and human intestinal immunity: same ballpark, different players; different rules, same score. Mucosal Immunol 4, 148-157.
15. Goozner, M. (2004). The $800 Million Pill: The Truth behind the Cost of New Drugs. Berkeley: University of California Press.
16. Graham, D. Y., Opekun, A. R., Osato, M. S., El-Zimaity, H. M., Lee, C. K., Yamaoka, Y., Qureshi, W. A., Cadoz, M. & Monath, T. P. (2004). Challenge model for Helicobacter pylori infection in human volunteers. Gut 53, 1235-1243.
17. He, Y., Xiang, Z. & Mobley, H. L. (2010). Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol 2010, 297505.
18. Higgins, S. C. & Mills, K. H. (2010). TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants. Curr Infect Dis Rep 12, 4-12.
19. Higgins, S. C., Jarnicki, A. G., Lavelle, E. C. & Mills, K. H. (2006). TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 177, 7980-7989.
20. Hotez, P. (2011). A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff (Millwood) 30, 1080-1087.
21. Huang, H., Ostroff, G. R., Lee, C. K., Specht, C. A. & Levitz, S.M. (2010). Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded b-glucan particles. mBio 1, e00164-10.
22. Karlsson, E. A., Sheridan, P. A. & Beck, M. A. (2010). Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol 184, 3127-3133.
23. Kaufman, D. R., De Calisto, J., Simmons, N. L., Cruz, A. N., Villablanca, E. J., Mora, J. R. & Barouch, D. H. (2011). Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity. J Immunol 187, 1877-1883.
24. Kool, M., Fierens, K. & Lambrecht, B. N. (2012). Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 61, 927-934.
25. Light, D. W., Andrus, J. K. & Warburton, R. N. (2009). Estimated research and development costs of rotavirus vaccines. Vaccine 27, 6627-6633.
26. Madico, G., Welsch, J. A., Lewis, L. A., McNaughton, A., Perlman, D. H., Costello, C. E., Ngampasutadol, J., Vogel, U., Granoff, D. M. & Ram, S. (2006). The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177, 501-510.
27. Marzetta, C. A., Lee, S. S., Wrobel, S. J., Singh, K. J., Russell, N. & Esparza, J. (2010). The potential global market size and public health value of an HIV-1 vaccine in a complex global market. Vaccine 28, 4786-4797.
28. McElligott, S. (2009). Addressing supply side barriers to introduction of new vaccines to the developing world. Am J Law Med 35, 415-441.
29. Mestas, J. & Hughes, C. C. (2004). Of mice and not men: differences between mouse and human immunology. J Immunol 172, 2731-2738.
30. Minassian, A. M., Ronan, E. O., Poyntz, H., Hill, A. V. & McShane, H. (2011). Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. PLoS ONE 6, e19840.
31. Moretto, M. M., Lawlor, E. M. & Khan, I. A. (2008). Aging mice exhibit a functional defect in mucosal dendritic cell response against an intracellular pathogen. J Immunol 181, 7977-7984.
32. Moxon, E. R. & Siegrist, C. A. (2011). The next decade of vaccines: societal and scientific challenges. Lancet 378, 348-359.
33. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C. & Steffen, R. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350, 896-903.
34. NHS (2010). Why aren't children in the UK vaccinated against chickenpox? http://www.nhs.uk/chq/Pages/1032.aspx Date accessed 5 October 2011.
35. Outterson, K. & Kesselheim, A. S. (2008). Market-based licensing for HPV vaccines in developing countries. Health Aff (Millwood) 27, 130-139.
36. Peng, S. L. (2005). Signaling in B cells via Toll-like receptors. Curr Opin Immunol 17, 230-236.
37. PhRMA (2010). Medicines in Development for Infectious Diseases. http://www.phrma.org/sites/default/files/354/infectious_diseases_2010.pdf Date accessed 4 October 2011.
38. Plahte, J. (2005). Tiered pricing of vaccines: a win-win-win situation, not a subsidy. Lancet Infect Dis 5, 58-63.
39. Pulendran, B. (2009). Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 9, 741-747.
40. Pulendran, B. & Ahmed, R. (2011). Immunological mechanisms of vaccination. Nat Immunol 12, 509-517.
41. Rozenbaum, M. H., van Hoek, A. J., Vegter, S. & Postma, M. J. (2008). Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 7, 753-782.
42. Rutstein, R. M., Rudy, B., Codispoti, C. & Watson, B. (1994). Response to hepatitis B immunization by infants exposed to HIV. AIDS 8, 1281-1284.
43. Salisbury, D., Ramsay, M. & Noakes, K. (2006). Varicella. In Immunisation Against Infectious Disease, pp. 421-442. London: The Stationary Office.
44. Sasaki, S., Sullivan, M., Narvaez, C. F., Holmes, T. H., Furman, D., Zheng, N. Y., Nishtala, M., Wrammert, J., Smith, K. & other authors (2011). Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 121, 3109-3119.
45. Sauerwein, R. W., Roestenberg, M. & Moorthy, V. S. (2011). Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 11, 57-64.
46. Schreibelt, G., Benitez-Ribas, D., Schuurhuis, D., Lambeck, A. J., van Hout-Kuijer, M., Schaft, N., Punt, C. J., Figdor, C. G., Adema, G. J. & de Vries, I. J. (2010). Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116, 564-574.
47. Sekaly, R. P. (2008). The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205, 7-12.
48. Sette, A. & Rappuoli, R. (2010). Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33, 530-541.
49. Seubert, A., Calabro, S., Santini, L., Galli, B., Genovese, A., Valentini, S., Aprea, S., Colaprico, A., D'Oro, U. & other authors (2011). Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A 108, 11169-11174.
50. The Global Polio Eradication Initiative (2010). http://www.polioeradication.org/ Date accessed 5 October 2011.
51. Thompson, K. M., Tebbens, R. J., Pallansch, M. A., Kew, O. M., Sutter, R. W., Aylward, R. B., Watkins, M., Gary, H. E., Jr, Alexander, J. & other authors (2008). The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health 98, 1322-1330.
52. von Bernuth, H., Picard, C., Jin, Z., Pankla, R., Xiao, H., Ku, C. L., Chrabieh, M., Mustapha, I. B., Ghandil, P. & other authors (2008). Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321, 691-696.
53. WHO (2008). The Top 10 Causes of Death. Fact Sheet No. 310. http://www.who.int/mediacentre/factsheets/fs310/en/index.html Date accessed 30 September 2011.
54. WHO (2009). Childhood vaccines at all-time high, but access not yet equitable. http://www.who.int/mediacentre/news/releases/2009/state_immunizaton_20091021/en/ Date accessed 4 October 2011.
55. WHO/UNICEF (2010). Global Immunization Data. http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf Date accessed 10 August 2011.